Loss of SFRP1 expression is associated with aberrant β-catenin distribution and tumor progression in mucoepidermoid carcinoma of salivary glands

Annals of Surgical Oncology

Volumn 17, Issue 8, 2010, Pages 2237-2246

  Lee, Chien Hsing ^a,b   Hung, Yi Jen ^b   Lin, Chih Yuan ^b   Hung, Pei Hsin ^b   Hung, Hsing Wen ^b   Shieh, Yi Shing ^a,b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BETA CATENIN; CYCLIN D1; SECRETED FRIZZLED RELATED PROTEIN 1; MEMBRANE PROTEIN; SFRP1 PROTEIN, HUMAN; SIGNAL PEPTIDE; TUMOR MARKER;

ADENOSQUAMOUS CARCINOMA; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CELL INVASION; CELL MIGRATION; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DNA METHYLATION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROMOTER REGION; SALIVARY GLAND CARCINOMA; TUMOR GROWTH; COLON POLYPOSIS; FEMALE; MALE; METABOLISM; METHYLATION; MORTALITY; ONCOGENESIS AND MALIGNANT TRANSFORMATION; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; SALIVARY GLAND TUMOR; SURVIVAL; TUMOR CELL LINE;

ADENOMATOUS POLYPOSIS COLI; BETA CATENIN; CARCINOMA, MUCOEPIDERMOID; CELL LINE, TUMOR; CYCLIN D1; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; METHYLATION; NEOPLASTIC PROCESSES; POLYMERASE CHAIN REACTION; PROGNOSIS; SALIVARY GLAND NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77954953165     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-0961-z     Document Type: Article

References (39)

1. Goode RK, Auclair PL, Ellis GL, et al. Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria. Cancer. 1998;82:1217-24.
2. Shieh YS, Chang LC, Chiu KC, et al. Cadherin and catenin expression in mucoepidermoid carcinoma: correlation with histopathologic grade, clinical stage, and patient outcome. J Oral Pathol Med. 2003;32:297-304.
3. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 2004;303:1483-7.
4. Kishida S, Yamamoto H, Ikeda S, et al. Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of beta-catenin. J Biol Chem. 1998;273:10823-6.
5. Miyoshi Y, Iwao K, Nagasawa Y, et al. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res. 1998;58:2524-7.
6. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281:1509-12.
7. Ashihara K, Saito T, Mizumoto H, et al. Mutation of beta-catenin gene in endometrial cancer but not in associated hyperplasia. Med Electron Microsc. 2002;35:9-15.
8. Shiratsuchi H, Nakashima T, Hirakawa N, et al. beta-Catenin nuclear accumulation in head and neck mucoepidermoid carcinoma: its role in cyclin D1 overexpression and tumor progression. Head Neck. 2007;29:577-84.
9. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17:9-26.
10. Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol. 2005;45:629-56.
11. Matsuda Y, Schlange T, Oakeley EJ, et al. WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth. Breast Cancer Res. 2009;11: R32.
12. Veeck J, Niederacher D, An H, et al. Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene. 2006;25:3479-88.
13. Wang JS, Guo M, Montgomery EA, et al. DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett's esophagus. Am J Gastroenterol. 2009;104:2153-60.
14. Dahl E, Wiesmann F, Woenckhaus M, et al. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. Oncogene. 2007;26:5680-91.
15. Stoehr R, Wissmann C, Suzuki H, et al. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest. 2004;84:465-78.
16. Sievers S, Fritzsch C, Lehnhardt M, et al. Hypermethylation of the APC promoter but lack of APC mutations in myxoid/round-cell liposarcoma. Int J Cancer. 2006;119:2347-52.
17. Urakami S, Shiina H, Enokida H, et al. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res. 2006;12:2109-16.
18. Odajima T, Sasaki Y, Tanaka N, et al. Abnormal beta-catenin expression in oral cancer with no gene mutation: correlation with expression of cyclin D1 and epidermal growth factor receptor, Ki-67 labeling index, and clinicopathological features. Hum Pathol. 2005;36:234-41.
19. Chung MT, Lai HC, Sytwu HK, et al. SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway. Gynecol Oncol. 2009;112:646-53.
20. Waki T, Tamura G, Sato M, et al. Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples. Oncogene. 2003;22:4128-33.
21. Marsit CJ, Karagas MR, Andrew A, et al. Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res. 2005;65:7081-5.
22. Issa JP, Ahuja N, Toyota M, et al. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 2001;61:3573-7.
23. Sato F, Harpaz N, Shibata D, et al. Hypermethylation of the p14 (ARF) gene in ulcerative colitis-associated colorectal carcinogenesis. Cancer Res. 2002;62:1148-51. (Pubitemid 34160301)
24. Bian YS, Osterheld MC, Fontolliet C, et al. p16 inactivation by methylation of the CDKN2A promoter occurs early during neo-plastic progression in Barrett's esophagus. Gastroenterology. 2002;122:1113-21.
25. Wong DJ, Paulson TG, Prevo LJ, et al. p16 (INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res. 2001;61:8284-9.
26. Kang GH, Shim YH, Jung HY, et al. CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res. 2001;61:2847-51.
27. Kaneto H, Sasaki S, Yamamoto H, et al. Detection of hypermethylation of the p16 (INK4A) gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut 2001;48:372-7.
28. Suzuki H, Watkins DN, Jair KW, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet. 2004;36:417-22.
29. Lodygin D, Epanchintsev A, Menssen A, et al. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res. 2005;65:4218-27.
30. Shih YL, Shyu RY, Hsieh CB, et al. Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma. Cancer. 2006;107:579-90.
31. Hsieh CL. Dependence of transcriptional repression on CpG methylation density. Mol Cell Biol. 1994;14:5487-94.
32. Matsuno N, Hoshino K, Nanri T, et al. p15 mRNA expression detected by real-time quantitative reverse transcriptase-polymerase chain reaction correlates with the methylation density of the gene in adult acute leukemia. Leuk Res. 2005;29:557-64.
33. Kawamoto K, Hirata H, Kikuno N, et al. DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines. Int J Cancer. 2008;123:535-42.
34. Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci. 2003;116:2627-34.
35. Bovolenta P, Esteve P, Ruiz JM, et al. Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. J Cell Sci. 2008;121:737-46.
36. Bafico A, Gazit A, Pramila T, et al. Interaction of frizzled related protein (FRP) with Wnt ligands and the frizzled receptor suggests alternative mechanisms for FRP inhibition of Wnt signaling. J Biol Chem. 1999;274:16180-7.
37. Hausler KD, Horwood NJ, Chuman Y, et al. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation. J Bone Miner Res. 2004;19:1873-81.
38. Lee HX, Ambrosio AL, Reversade B, et al. Embryonic dorsalventral signaling: secreted frizzled-related proteins as inhibitors of tolloid proteinases. Cell. 2006;124:147-59.
39. Yabe T, Shimizu T, Muraoka O, et al. Ogon/Secreted Frizzled functions as a negative feedback regulator of Bmp signaling. Development. 2003;130:2705-16.